Probiotics (Multi-strain Blends)
Multi-strain probiotic blends combine live microbes, usually from Lactobacillus and Bifidobacterium and sometimes Bacillus, Streptococcus or Saccharomyces. Effects depend on the exact strains, dose and setting, so a result for one product does not carry over to another; strain-specific evidence is on the pages for single strains such as Lactobacillus rhamnosus GG, Saccharomyces boulardii, Limosilactobacillus reuteri DSM 17938 and Bifidobacterium lactis. Pooled reviews of many different products found less diarrhea in people taking antibiotics, fewer cases of C. difficile-associated diarrhea (low certainty) and fewer people with at least one upper respiratory infection (low certainty). In adults with IBS, some strains and combinations may ease symptoms, but certainty is low to very low. Serious infections have been reported in critically ill people and preterm infants given probiotics.
Benefits
Digestive support during antibiotic courses
Pooled trials found less antibiotic-associated diarrhea with probiotics: 42 trials in adults (risk ratio 0.63, moderate certainty, with no difference where baseline risk was low) and 33 trials in children (8% versus 19%, moderate certainty), where 5 billion CFU a day or more worked better. Probiotics were given alongside antibiotics, and products varied widely.
Gut support for people at high risk during antibiotic use
A Cochrane update of 38 trials (13,179 people taking antibiotics) found C. difficile-associated diarrhea in 1.6% with probiotics versus 3.2% with control (low certainty), about one case prevented per 65 people. The earlier version found the benefit only in trials where more than 5% of controls were affected. Detection of C. difficile in stool was not clearly reduced.
Bowel comfort, depending on the strain
A meta-analysis of 82 placebo-controlled trials (10,332 adults with IBS) found that some strains and combinations may ease overall symptoms, abdominal pain or bloating, but certainty was low to very low in almost all analyses, and very low for combination products. Side effects were not more common than with placebo. The American Gastroenterological Association recommends probiotics for IBS only within clinical trials.
Immune support in upper respiratory tract trials
A Cochrane review of 23 trials (6,950 children, adults and older people) found probiotics may reduce the number of people with at least one upper respiratory infection (risk ratio 0.76; 16 trials, 4,798 people; low certainty) and likely reduce antibiotic use for these infections (0.58, moderate certainty). Most trials used one or two strains rather than multi-strain blends, so results do not apply to every blend.
Mechanism of action
Resistance to gut pathogens
Antibiotics can disturb the gut's microbial community, which may lower its resistance to microbes such as C. difficile, and probiotics are studied as a way to support that resistance. In the Cochrane update, probiotics lowered C. difficile-associated diarrhea but did not clearly reduce C. difficile detection in stool, so how they act is not settled.
Clinical trials
Cochrane systematic review and meta-analysis of randomized trials of probiotics (any strain or dose, single strains and combinations) versus placebo, alternative prophylaxis or no treatment in adults and children receiving antibiotics for any reason; 28 included studies had authors affiliated with or funded by probiotic companies; the review itself had no funding. (Esmaeilinezhad et al. 2025, Cochrane Database Syst Rev)
47 randomized trials (15,260 adults and children taking antibiotics); 38 trials (13,179 people) reported C. difficile-associated diarrhea.
C. difficile-associated diarrhea occurred in 1.6% with probiotics versus 3.2% with control (risk ratio 0.50; low certainty), about one case prevented per 65 people. Detection of C. difficile in stool was not clearly reduced (14.9% versus 16.2%, not significant). Antibiotic-associated diarrhea was 23% versus 27.4% (low certainty), and adverse events were probably slightly fewer with probiotics (10.9% versus 12.2%; moderate certainty, not statistically significant).
Cochrane review of 33 randomized trials of probiotics given to children receiving antibiotics, versus active, placebo or no treatment control; probiotics tested included Bacillus, Bifidobacterium, Clostridium butyricum, Lactobacilli, Lactococcus, Leuconostoc cremoris, Saccharomyces or Streptococcus, alone or in combination. (Guo et al. 2019, Cochrane Database Syst Rev)
6,352 children aged 0 to 18 years.
Antibiotic-associated diarrhea occurred in 8% of children on probiotics versus 19% of controls (RR 0.45; moderate certainty). Doses of 5 billion CFU/day or more were more effective than lower doses. No serious adverse events were reported in the 24 trials that tracked them. Risk of bias was high in 20 of the 33 studies.
Cochrane review of 23 randomized trials comparing probiotics with placebo or no treatment for preventing acute upper respiratory tract infections; most trials used one or two strains, such as Lactobacillus plantarum HEAL9 or Lactobacillus paracasei 8700:2 or N1115, at 10^9 or 10^11 CFU a day for more than three months; the review authors declared no conflicts. (Zhao et al. 2022, Cochrane Database Syst Rev)
6,950 children, adults and older people.
The supplements may reduce the number of people with at least one infection (RR 0.76; 16 trials, 4,798 people; low certainty), the episode duration (by about 1.2 days; low certainty) and antibiotic use for these infections (RR 0.58; moderate certainty), without more adverse events (low certainty). The pooled products differed from trial to trial.
Systematic review and meta-analysis of randomized placebo-controlled trials of probiotics in adults with IBS, analyzed by strain or combination, including Escherichia strains, Lactobacillus plantarum 299V, Saccharomyces cerevisiae I-3856, Bifidobacterium strains, Bacillus strains and combination products such as LacClean Gold S and Duolac 7s. (Goodoory et al. 2023, Gastroenterology)
82 trials with 10,332 adults with IBS.
Some strains and combinations may improve global symptoms, abdominal pain or bloating, but certainty in the evidence was low to very low across almost all analyses (moderate only for Escherichia strains on global symptoms; very low for combination products on every outcome), and only 24 trials were at low risk of bias. Adverse events were not more common with probiotics (55 trials).
Systematic review and meta-analysis of randomized trials in adults given antibiotics, comparing probiotics with placebo, another dose or strain, or no treatment; subgroup analyses by species and dose; authors declared no competing interests. (Goodman et al. 2021, BMJ Open)
42 trials with 11,305 adults taking antibiotics.
Probiotics given with antibiotics lowered antibiotic-associated diarrhea (risk ratio 0.63; moderate GRADE quality). Higher doses of the same probiotic did better than lower doses, and only certain species, mainly Lactobacillus and Bifidobacterium, were effective. Trials with low baseline risk showed no difference; those with moderate or high baseline risk did.
Systematic review and meta-analysis of randomized trials of Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus and/or Bacillus probiotics; most were Lactobacillus based, alone or combined, and strains were poorly documented. (Hempel et al. 2012, JAMA)
82 trials met inclusion criteria; 63 trials with 11,811 participants were pooled.
Probiotics were associated with less antibiotic-associated diarrhea (risk ratio 0.58; number needed to treat 13). Results were heterogeneous, and the evidence was insufficient to show whether the effect varies by population, antibiotic or probiotic preparation.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Probiotics (Multi-strain Blends)
What is the recommended dosage of Probiotics?
No single dose is established, and doses varied by product in the reviews. Most respiratory trials used 1 billion or 100 billion CFU a day for more than three months, and in children taking antibiotics, 5 billion CFU a day or more worked better than lower doses. The IBS meta-analysis reported results by strain or combination rather than by dose, so follow the dose used in research on the specific product.
Does the strain matter, or just the species?
The strain matters most. Reviews found results differed by strain and combination, so 'Lactobacillus rhamnosus GG' or 'Bifidobacterium infantis 35624' tells you far more than just 'Lactobacillus.' For strain-specific evidence, see our pages on Lactobacillus rhamnosus GG, Saccharomyces boulardii, Limosilactobacillus reuteri DSM 17938, Bifidobacterium lactis (BB-12 / HN019), Bifidobacterium infantis 35624 and Lactobacillus plantarum 299v.
When should I take a probiotic?
Follow the product label. In the antibiotic trials pooled by the reviews, probiotics were given alongside the antibiotic course; ask your pharmacist how to time a probiotic around antibiotic doses.
How long until a probiotic works?
It depends on the goal. Children's antibiotic trials followed participants for 5 days to 12 weeks, and most respiratory trials gave probiotics for more than three months. Choose a strain with research on your goal and allow the time used in those studies.
Is Probiotics safe, and does it have side effects?
In the pooled trials, side effects were mostly minor digestive complaints such as gas, bloating, nausea, cramping or soft stools, and they were not more common than with placebo or control. The risk of harmful effects is greater in people with severe illness or a weakened immune system: bloodstream infections traced to the probiotic product have been reported in intensive care patients, and the FDA has warned that preterm infants given probiotics are at risk of invasive, potentially fatal infection. Ask a doctor first in these situations.
What is Probiotics?
Multi-strain probiotic blends combine live microbes, usually from Lactobacillus and Bifidobacterium and sometimes Bacillus, Streptococcus or Saccharomyces. Effects depend on the exact strains, dose and setting, so a result for one product does not carry over to another; strain-specific evidence is on the pages for sing…
What is Probiotics used for?
Probiotics is researched primarily for Immune Support and Gut Health. Pooled trials found less antibiotic-associated diarrhea with probiotics: 42 trials in adults (risk ratio 0.63, moderate certainty, with no difference where baseline risk was low) and 33 trials in children (8% versus 19%, moderate certainty)…
Does Probiotics interact with any medications?
Possible interactions include: Antibiotics: in the trials pooled by the reviews, probiotics were given alongside antibiotics; ask your pharmacist how to time a probiotic around antibiotic doses. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Probiotics?
NutraSmarts rates the evidence for Probiotics as Moderate (3 out of 5). It is backed by 6 study summaries and 11 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(11 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.PubMedUsed to support: Earlier (2017) version of the Cochrane C. difficile review: 31 trials (8,672 participants) found C. difficile-associated diarrhea in 1.5% with probiotics versus 4.0% with control (RR 0.40, moderate certainty). In a post hoc analysis the benefit was seen in trials with baseline risk above 5% (3.1% versus 11.6%) but not at baseline risk of 5% or less; C. difficile detection in stool was not reduced. Superseded by the 2025 update.
- Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827. doi: 10.1002/14651858.CD004827.pub5.PubMedUsed to support: Cochrane review of 33 trials in 6,352 children taking antibiotics: probiotics lowered antibiotic-associated diarrhea from 19% to 8% (RR 0.45, moderate certainty), and doses of at least 5 billion CFU a day were more effective than lower doses. Follow-up lasted 5 days to 12 weeks. No serious adverse events attributable to probiotics were reported in the 24 trials that reported adverse events, but observational reports describe serious events in severely debilitated or immunocompromised children, including those with central venous catheters.
- Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-69. doi: 10.1001/jama.2012.3507.PubMedUsed to support: Meta-analysis of 63 trials (11,811 participants): probiotics were associated with lower antibiotic-associated diarrhea (RR 0.58). Strains were poorly documented, and the evidence could not show which probiotic preparations work best.
- AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697-705. doi: 10.1053/j.gastro.2020.05.059.PubMedUsed to support: AGA guideline. Recommendation 6: in children and adults with IBS, use probiotics only in the context of a clinical trial. Recommendation 2 suggests specific strains or combinations (such as S. boulardii) for preventing C. difficile infection in people taking antibiotics, not probiotics in general. Recommendation wording read on the AGA guideline summary page (gastro.org).
- Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2022;8(8):CD006895. doi: 10.1002/14651858.CD006895.pub4.PubMedUsed to support: Cochrane review of 23 trials (6,950 children, adults and older people): probiotics may reduce the number of people with at least one upper respiratory tract infection (RR 0.76, low certainty) and likely reduce antibiotic use for these infections (RR 0.58, moderate certainty). Most trials used one or two strains at 10^9 or 10^11 CFU a day for more than three months; adverse events were minor, mostly digestive.
- Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5):1206-1218. doi: 10.1053/j.gastro.2023.07.018.PubMedUsed to support: Meta-analysis of 82 trials in 10,332 adults with IBS: some strains or combinations may help global symptoms, abdominal pain or bloating, but certainty was low to very low across almost all analyses; adverse events were not more common with probiotics.
- Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2025;9(9):CD006095. doi: 10.1002/14651858.CD006095.pub5.PubMedUsed to support: 2025 update of the Cochrane review (47 trials, 15,260 people taking antibiotics). In 38 trials, C. difficile-associated diarrhea was 1.6% with probiotics versus 3.2% with control (RR 0.50, low certainty; one case prevented per 65 people); C. difficile in stool was not significantly reduced (RR 0.87); antibiotic-associated diarrhea RR 0.67 (low certainty); adverse events probably slightly fewer (RR 0.86, 95% CI 0.72 to 1.01, not statistically significant; moderate certainty), most commonly abdominal cramping, nausea, fever, soft stools, flatulence and taste disturbance. 28 studies had authors affiliated with or funded by probiotic companies. The authors judged short-term use likely not associated with adverse effects in people receiving antibiotics who are not immunocompromised.
- Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e043054. doi: 10.1136/bmjopen-2020-043054.PubMedUsed to support: Meta-analysis of 42 trials (11,305 adults): probiotics given with antibiotics lowered antibiotic-associated diarrhea (RR 0.63, moderate GRADE quality). Higher doses of the same probiotic did better than lower doses, only certain species (mainly Lactobacillus and Bifidobacterium) were effective, and trials with low baseline risk showed no difference. No competing interests declared.
- Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019;25(11):1728-1732. doi: 10.1038/s41591-019-0626-9.PubMedUsed to support: Hospital study (not a trial) of intensive care patients: Lactobacillus bloodstream infection was markedly more common in patients given a probiotic than in those not given one, and whole-genome sequencing showed the blood isolates were inseparable from the Lactobacillus in the probiotic product, supporting direct transmission from the capsule to the bloodstream.
- Probiotics: Usefulness and Safety NCCIH (National Institutes of Health). 2019;Last updated August 2019; read in 2026..SourceUsed to support: Official NIH fact sheet, not PubMed-indexed, read in 2026. The risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems; for high-risk individuals such as premature infants or seriously ill hospital patients, risks should be weighed against benefits; possible harms include infections; some products have been reported to contain microorganisms other than those on the label; and in 2023 the FDA warned that premature infants given probiotics are at risk of severe, potentially fatal infections.
- FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. FDA News Release. 2023;October 26, 2023; read in 2026..SourceUsed to support: Official FDA statement, not PubMed-indexed, read in 2026. Preterm infants given probiotic products are at risk of invasive, potentially fatal disease or infection; FDA reported one infant death in 2023 and more than two dozen other US adverse events since 2018, and states it has not approved any probiotic product for use as a drug or biological product in infants of any age.